参考文献/References:
[1] 中国老年学学会心脑血管专业委员会.非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家共识.中国心房颤动抗凝的现状与未来[J].中国心血管病研究, 2014,12(9): 769-770.
[2] Madan S,Shan S,Partovi S,et al.Use of novel anticoagulant agents in atrial fibrillation:current evidence and future perspective[J].Cardiovasc Diagn Ther,2014,4(4):314-323.
[3] Huber K,Connolly SJ,Kher A,et al.Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation[J].Int J Clin Pract,2013,67(6):516-526.
[4] Connolly SJ,Wallentin L,Ezekowitz MD,et al.The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation(RELY-ABLE)study[J].Circulation,2013,128(3):237-243.
[5] Hohnloser SH, Oldgren J, Yang S,et al.Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY(Randomized Evaluation of Long-Term Anticoagulation Therapy)trial[J].Circulation,2012,125(5):669-676.
[6] Uchino K,Hernandez AV.Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials[J].Arch Intern Med,2012,172(5):397-402.
[7] U.S.Food and Drug Administration[J/OL]. Availableat:http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm. Accessed April 16, 2014.
[8] January CT,Wann LS,Alpert JS,et al. 2014 ACCF/AHA/HRS Guideline for the management of patients with atrial fibrillation.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the Heart Rhythm Society[J].J Am Coll Cardiol, 2014,4(21):e1-e76.
[9] Lee A,Rajaratnam R.The current and future role of the novel oral anticoagulants-indications beyond atrial fibrillation[J].Heart Lung Circ,2014,23(1):2-9.
[10] Shavadia J,Welsh RC.Acute management of ST-elevation myocardial infarction patients taking dabigatran[J].Can J Cardiol,2013,29(11):1531.e13-e14.
[11] Ferreira J,Ezekowitz MD,Connolly SJ,et al.Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial[J].Eur J Heart Fail,2013,15(9):1053-1061.
[12] Birnie DH,Healey S,Wells GA,et al.Pacemaker or defibrillator surgery without interruption of anticoagulation[J].N Engl J Med,2013,368(22):2084-2093.
[13] Du L,Zhang Y,Wang W,et al.Perioperative anticoagulation management in patients on chronic oral anticoagulant therapy undergoing cardiac devices implantation: a meta-analysis[J].Pacing Clin Electrophysiol,2014,37(11):1573-1586.
[14] Kosiuk J,Koutalas E,Doering M,et al.Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study[J].Circ J,2014,78(10):2402-2407.
[15] Terrovitis JV,Ntalianis A,Kapelios CJ,et al.Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device[J].Hellenic J Cardiol,2015,56(1):20-25.
[16] Eikelboom JW,Connolly SJ,BrueckmannM,et al.Dabigatran versus warfarin in patients with mechanical heart valves[J]. N Engl J Med,2013,369(13):1206-1214.
[17] Kuwauchi S,Watanabe S,Abe K,et al.Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate[J].Ann Thorac Surg,2013,96(5):1863-1864.
[18] Sharma S,Singh S,Sandhu R,et al.Case report series of left atrial thrombus formation in patients on dabigatran therapy[J].Am J Ther,2014,21(3):e71-e74.
[19] Gasparovic H,Petricevic M, Biocina B. Dabigatran in patients with mechanical heart valves[J].N Engl J Med,2014,370(4):383.
[20] Kaku B.Intra-cardiac thrombus resolution after anticoagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report[J]. Med Case Rep,2013,7:238.
[21] Omae T,Kanmura Y.Management of postoperative atrial fibrillation[J].J Anesth,2012,26(3):429-437.
[22] Fieland D, Taylor M. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies[J].Ann Pharmacother,2012,46(1):e3.
[23] Macellari F,Paciaroni M,Agnelli G,et al. Perioperative stroke risk in nonvascular surgery[J].Cerebrovasc Dis,2012,34(3):175-1781.
[24] Shafi ST,Negrete H,Roy P,et al.A case of dabigatran-associated acute renal failure[J].WMJ,2013,112(4):173-175.
[25] Lee MJ,Jang HM,Jeong WK,et al.The need for a coagulation assay after initiation of new oral anticoagulants in patients with renal dysfunction:a case report[J].J Clin Neurol,2015,11(4):395-397.
[26] Hapgood G,Butler J,Malan E,et al.The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples[J].Thromb Haemost,2013,110(2):308-315.
[27] Grottke O,van Ryn J, Spronk HM,et al.Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model[J].Crit Care,2014, 18(1):R27.
[28] Schiele F,van Ryn J,Canada K,et al. A specific antidote for dabigatran: functional and structural characterization[J].Blood,2013,121(18):3554-3562.